Humans are exposed to various external environmental factors. Food intake is one of the most influential factors impacting daily lifestyle. Among nutrients obtained from foods, omega-3 polyunsaturated fatty acids (PUFAs) have various beneficial effects on inflammatory diseases. Furthermore, omega-3 PUFA metabolites, including resolvins, are known to demonstrate strong anti-inflammatory effects during allergic and inflammatory diseases; however, little is known regarding the actual impact of these metabolites on skin diseases. In this review, we focused on metabolites that have strong anti-inflammatory actions in various inflammatory diseases, as well as those that present antitumor actions in malignancies, in addition to the actual effect of omega-3 PUFA metabolites on various cells.

Keywords: ω3 polyunsaturated fatty acids, resolvin, protectin, maresin, metabolites

INTRODUCTION

The environment is fundamental for humans to live on earth and influences various physiological and pathological functions in the human body (1, 2). Food intake is an essential task for animals to drive their body and allows us to reconstruct body structure from nutrients (3). Among nutrients derived from foods, fatty acids are a component of cells and are known to control various cellular functions (4, 5). Omega-3 polyunsaturated fatty acids (PUFAs) are composed of 18 or more carbon chains, with a double bond three atoms away from the terminal methyl group, and are mainly classified into three representative lipids: α-linoleic acid (ALA), docosahexaenoic acids (DHA), and eicosapentaenoic acid (EPA). ALA is enzymatically converted to EPA and subsequently converted into DHA (6). These conversions primarily occur in the liver and are extremely limited owing to the enzyme concentration in the human body (7–9). Therefore, it is reasonable to derive DHA and EPA directly from foods and/or dietary supplements enriched in fish oils.

Omega-3 PUFAs have been known to demonstrate anti-inflammatory actions in various inflammatory diseases, including psoriasis, inflammatory bowel disease, asthma, and rheumatoid arthritis (10–12). In recent studies, omega-3 PUFA metabolites, such as resolvins (Rvs) and maresins, have revealed potent anti-inflammatory actions. Protectins (PD) and D-series Rvs are converted from DHA by 15-lipoxygenase, whereas E-series Rvs are produced from EPA by the cytochrome P450 pathways or acetylated cyclooxygenase-2. These metabolites have strong anti-inflammatory actions in various inflammatory diseases, such as animal models of asthma (13) and colitis (14), as well as antitumor actions in malignancies; however, little is known regarding their role in skin diseases. This review focused on the therapeutic potential of omega-3 PUFA metabolites for inflammatory skin diseases, as well as antitumor actions against cutaneous tumors.
ANTI-INFLAMMATORY ACTION ON IMMUNE CELLS AND EPITHELIAL CELLS

Reportedly, omega-3 PUFA metabolites have demonstrated various actions on immune and epithelial cells. In this section, we first reviewed the influence of omega-3 PUFA metabolites on each cell type, including dendritic cells (DCs)/macrophages, T cells/regulatory T cells (Tregs)/B cells, neutrophils, and epithelial cells, which are known to be present in the skin (Table 1).

DCs/Macrophages

DCs and macrophages play central roles in the acquired immune system to determine the direction of immune responses. As antigen-presenting cells, they take up antigens via phagocytic mechanisms to present antigens to T cells, to determine the direction of the immune response.

Phagocytosis is promoted by resolvin E1 (RvE1) (15–20), resolvin D1 (RvD1) (20, 34–37), resolvin D2 (RvD2) (20, 64), resolvin D3 (RvD3) (67, 68), resolvin D5 (RvD5) (70), protectin D1 (PD1) (15), and maresin 1 (MaR1) (82). For apoptotic cells, the macrophage phagocytosis is enhanced by RvE1 (15), PD1 (15), and RvD1 (34). Phagocyte-dependent bacterial clearance is enhanced by maresin 1 (MaR1) (82), RvD2 (64), RvD3 (67), and RvD5 (70).

Inflammatory cytokine production is negatively regulated by RvE1 (16, 20, 23), RvD1 (20, 38, 40), RvD2 (20, 38), RvD3 (71), and MaR1 (38, 78–80). RvE1, RvD1, and RvD2 suppress chemokine (C-C motif) ligand 4 (CCL4), CCL5, interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF)-α induced by human monocyte-derived macrophages co-cultured with tumor cell debris (20), IL-12 by DCs stimulated with pathogen extract (23), and superoxide production by macrophages stimulated with cigarette smoke (16). In macrophages stimulated with lipopolysaccharide (LPS), RvD1, RvD2, and MaR1 suppress IL-1β and IL-6 (38, 78, 79). In contrast, MaR1 promotes the production of the inhibitory cytokine IL-10 (81).

DCs/macrophages play central roles in antigen presentation, as well as migration into antigen-presenting sites for T cells to initiate their active forms. RvD1 suppresses antigen presentation by suppressing major histocompatibility complex (MHC) class II and CD40 expression (39). Additionally, DC migration and infiltration into inflamed tissues are negatively regulated by RvE1 (22, 23) and RvD1 (43). RvE1 suppresses the migration of DCs in the skin and into draining lymph nodes, attenuating the acquired immune response (22), while RvD1 attenuates the increased infiltration of M1 macrophages (43).

Owing to the characteristics of antigen-presenting cells as a control tower in the immune response, the polarization of macrophages determines the direction of inflammatory responses. M1 macrophages are induced by interferon (IFN)-γ, a microbial component. M1 macrophages produce inflammatory cytokines and induce effector cells in polarized Th1 responses. M1 polarization is reportedly suppressed by RvD1 (44) and RvD2 (44). M2 macrophages are generated during enhanced Th2 reactions,

Table 1: Cell-specific action of SPMs.

| DC/Mφ | T cell/Treg/B cell | Neutrophil | Epithelial cell |
|-------|------------------|------------|----------------|
| RvE1  | Phagocytosis † (15–20) M2 polarization † (21) Migration † (22) (23) TNFα, IL-6, IL-8, CCL4, and CCL15 † (20), IL-12 † (23), Superoxide production † (18) | Infiltration † (24) T-cell trafficking ↓ (21) | Infiltration † (17, 25) CXC1/4, CCR2/6 † (21) ROS† (26, 27) Phagocytosis† (26, 28) Apoptosis† (29) |
| RvD3  | No report | | |
| RvD1  | Phagocytosis † (20, 34–37) COX-2 and IL-1β, IL-6 † (58), TNFα, IL-6, IL-8, CCL4, and CCL15 † (20) | Migration † (62) | No report |
| RvD2  | Phagocytosis † (20, 64) TNFα, IL-6, IL-8, CCL4, and CCL15 † (20), COX-2 and IL-1β, IL-6 † (58) | Migration † (62) | Phagocytosis† (63) |
| RvD3  | Phagocytosis † (67, 68) | | |
| RvD5  | Phagocytosis † (70) | | |
| PD1   | Phagocytosis † (15) Inflammatory cytokine suppression (71) | | |
| MaR1  | COX-2, IL-1β † (39), iNOS, IL-1β, IL-6, TNFα † (78), ROS, IL-1β, TNFα, IL-6, and INF-γ † (79), ROS †, apoptosis † (80) M2 polarization, IF-10† (81) Phagocytosis † (62) | | |

Table 1: Cell-specific action of SPMs.
promoting parasite killing (88), tissue repair (89), and immunoregulatory functions (90). M2 polarization is positively regulated by RvD1 (44–50), RvD2 (44), and MaR1 (91).

**T Cells/Tregs/B Cells**

T cells can respond to pathogens by direct contact with the antigen derived from the pathogen and need to migrate to sites in the presence of the antigen. Reportedly, T cell migration is regulated by RvE1 (21, 24), RvD1 (52), and PD1 (72). RvE1 decreases the infiltration of Th1 and Th17 cells (24). RvE1 suppresses T cell infiltration by decreasing the production of RANTES in vascular smooth muscle cells (21).

After the initiation of immune responses by antigen-presenting cells, naïve T cells develop T cell responses as an appropriate direction of inflammatory immune responses. RvD1, RvD2, and PD1 suppress inflammatory cytokine production (51). RvD1, RvD2, and PD1 reduce Th1 and Th17 cytokine production (51).

Tregs are promising cells for the maintenance of immune homeostasis and tolerance (92). T cell-mediated autoimmune diseases and allergies are closely related to their deficiency or dysfunction. RvD1, RvD2, and PD1 are known to contribute to the inhibition of immune reactions by increasing Tregs (51).

B cells play an important role in the adaptive immune system. The activation of B cells is induced following antigen recognition, differentiating to form plasma cells for antibody secretion. RvD1 influences immunoglobulin production by B cells and increases IgM and IgG production (54), as well as reduces IgE production (55).

**Neutrophils**

Neutrophils have various functions, including phagocytosis and antimicrobial peptide production (93). Reportedly, neutrophil phagocytosis is positively regulated by RvE1 (26, 28), RvD1 (63), and RvD3 (67). In phagocytes, NADPH oxidase is essential for neutrophil microbicidal activity (94). Furthermore, reactive oxygen species (ROS) generation in neutrophils is promoted by RvE1 (26, 27) and RvD3 (67). In addition, neutrophil migration is suppressed by RvE1 (17, 25), RvE3 (32, 33), RvD1 (36, 52, 56–61), RvD2 (64, 65), RvD3 (68), PD1 (73–75), and MaR1 (84, 85). RvE1 decreases chemokine receptor expression, including C-C chemokine receptor type 2 (CCR2), CCR6, chemokine (C-X-C motif) receptor 1 (CXCR1), and CXCR4 (21), as well as chemotaxis (26). RvD1 decreases CXCR4 expression (62). Moreover, RvD2 allows neutrophils to enhance their access to the dermis; however, RvD2 demonstrates a protective role against neutrophil-mediated damage (66).

Apoptotic neutrophils progress toward secondary necrosis mediated by the release of caspase 3-processed danger signals (93). Neutrophil apoptosis is reportedly enhanced by RvE1 (29), RvD1 (50), PD1 (74), and MaR1 (86). These metabolites enhance apoptotic cell phagocytosis of macrophages, suppressing secondary necrosis-mediated inflammation.

**Epithelial Cells**

Epithelial cells act as the first line of defense against the external environment. As the outermost organ layer, epithelial cells induce inflammatory cytokine and chemokine production to amplify the response to external stimuli. Inflammatory cytokine production is negatively regulated by MaR1 (87). Furthermore, MaR1 suppresses the production of CXCL1, IL-6, IL-8, and TNF-α by bronchial epithelial cells (87).

As the outer organ layer, epithelial cells exhibit migration and proliferation to shield the defect of the first line of defense against external stimuli. RvE1 enhances epithelial cell migration (30, 31), RvD3 promotes lung epithelial cell proliferation (69), while RvD1 and PD1 exhibit protective effects toward epithelial cells. Furthermore, RvD1 promotes epithelial barrier integrity (57). PD1 is shown to afford protection against repetitive oxidative stress-induced apoptosis (76, 77).

**DIFFERENT FUNCTIONS OF PUFA METABOLITES ON IMMUNE CELLS AND EPITHELIAL CELLS**

There are some different effects of PUFA metabolites in immune cells and epithelial cells. RvE1 suppresses immune cell migration (22, 23) while it promotes epithelial cell migration (30, 31). In addition, PD1 promotes apoptosis of neutrophils (74); however, it enhances anti-apoptosis in epithelial cells (76, 77). Although the detailed mechanism remains unclear, a possible other point of action might exist in each different type of cell, because they are located in different body sites and surface layers, which are given the appropriate role in the body.

**THE ANTI-INFLAMMATORY ACTION OF PUFA METABOLITES ON SKIN DISEASES**

Several reports have highlighted the anti-inflammatory actions of omega-3 PUFA metabolites on inflammatory skin diseases, including psoriasis, atopic dermatitis, contact hypersensitivity, and ultraviolet (UV) radiation. Furthermore, the antitumor effects of PUFA metabolites on squamous cell carcinoma and melanoma have been reported (Table 2).

| Inflammatory skin disease | Omega-3 PUFA metabolites |
|---------------------------|---------------------------|
| Psoriasis                 | MaR1 (95)                 |
|                           | RvE1 (96)                 |
|                           | RvD1 (97)                 |
| Atopic dermatitis         | RvE1 (88)                 |
| Contact dermatitis        | RvE1 (92)                 |
| UV radiation              | MaR1 (98)                 |
| Wound healing             | PD1 (48)                  |
|                           | RvD1 (100)                |
| Malignancy                |                           |
| Squamous cell carcinoma   | RvD2 (101)                |
| Malignant melanoma        | RvD1 (20)                 |
|                           | RvD2 (20)                 |
Psoriasis and PUFA Metabolites

Psoriasis is a representative inflammatory skin disease characterized by scaly erythematous plaques with epidermal hyperplasia (102). Although the underlying mechanism of psoriasis remains unclear, recent studies have revealed some predominant pathways underlying pathological conditions, as well as the contribution of the TNF/IL-23/IL-17 axis (103). Current biologics targeting IL-17, IL-23, and TNF-α play critical roles in the pathogenesis of psoriasis (104).

Reportedly, MaR1 impairs imiquimod-induced psoriasis-like skin inflammation and IL-23 subcutaneous injection-induced skin inflammation (95). MaR1 decreases lymphocyte and neutrophil infiltration, dermal edema, and epithelial hyperplasia. MaR1 inhibits the production of IL-17A by CD4+ and γδ TCRmed cells. Consequently, MaR1 attenuates IL-23 receptor expression on CD4+ and γδ TCRmed cells by inhibiting retinoic acid-related orphan receptor gamma t (RORγt) in clathrin-dependent IL-23 receptor internalization.

RvE1 impairs imiquimod-induced psoriatic dermatitis (96). Furthermore, IL-17-producing cells and neutrophils are reduced in the skin following RvE1 treatment. Reportedly, IL-23 and IL-17 are downregulated by RvE1. IL-23 production by DCs, as well as the migration of DCs and IL-17 producing cells, is suppressed by RvE1.

RvD1 reduces acanthosis and hyperkeratosis induced by imiquimod (97). Inflammatory cell infiltration into the dermis is reduced following treatment with RvD1. Consistently, IL-17, IL-23, and TNF-α are decreased by RvD1.

Atopic Dermatitis (AD) and PUFA Metabolites

AD is a representative Th2-mediated chronic inflammatory skin disease characterized by inflamed and irritative itch skin inflammation (105). Several factors are involved in the various environmental factors that drive Th2 dominant skin inflammation, including skin barrier disruption (106, 107), pathogens (108), and prostanoids (109). In NC/Nga mice, RvE1 demonstrates anti-inflammatory actions in repeated hapten application-induced AD-like skin inflammation (98). RvE1 suppresses IL-4 and IFN-γ production by T cells, as well as serum IgE levels, and reduces the infiltration of eosinophils, mast cells, and T cells in skin lesions.

Contact Dermatitis and PUFA Metabolites

Contact dermatitis is a common cutaneous allergic reaction that depends on the acquired immune response (110, 111). RvE1 impairs the inflammatory response in contact hypersensitivity during the sensitization and elicitation phases (22). During the sensitization phase, RvE1-treated mice exhibit significantly reduced DC migration into draining lymph nodes, subsequently reducing the number of central and effector memory T cells. Consistently, antigen-specific T cell proliferation and IFN-γ production are reduced by RvE1. In the elicitation phase, RvE1 impairs DC cluster formation, which is essential for the development of elicitation phase inflammation, subsequently suppressing the number of IFN-γ-producing CD8+ T cells in the skin.

UV Radiation and MaR1

UV radiation is a representative environment-related skin inflammation that causes acute inflammation characterized by skin inflammation after sun exposure (112). MaR1 suppresses skin swelling as well as macrophage infiltration induced by UVB irradiation (99). Furthermore, MaR1 inhibits UVB irradiation-induced keratinocyte apoptosis, production of inflammatory cytokines, IL-1β and TNFα, and oxidative stress.

Wound Healing and PUFA Metabolites

Damage induced by external factors destroys the skin surface, resulting in skin defects that appear as a wound. As the skin acts as a barrier against the external environment, wounds allow outside pathogens and irritants to infiltrate the body and cause skin inflammation (113). PD1 and RvD1 promote skin wound healing (48, 100). In diabetic wounds, RvD1 enhances macrophage phagocytosis, promoting wound closure owing to the reduced number of apoptotic cells (48). Furthermore, PD1 promotes wound closure (100). Skin wounds promote the synthesis of PD1 in the skin; however, in diabetes, the skin suppresses PD1 production. Macrophages are one of the main sources of PD1 in skin wounds and are known to contribute to the development of inflammation and oxidative stress reactions during acute inflammation in diabetic wounds.

Antitumor Effects of PUFA Metabolites

Squamous cell carcinoma is a keratinocyte-derived malignancy, and the advanced clinical stage of this malignancy remains refractory to current systemic treatments (114). RvD2 suppresses squamous cell carcinoma development (101) and decreases inflammatory chemokines and cytokines, including CXCL10, IL-6, monocyte chemoattractant protein-1 (MCP-1), and TNF-α, by cancer cells. In squamous cell carcinoma, RvD2 decreases the infiltration of neutrophils and suppresses myeloperoxidase (MPO) activity. Additionally, RvD2 enhances the M2 macrophage population and their effecrosis.

Malignant melanoma is a malignancy derived from melanocytes with severe life-threatening clinical behavior owing to a lack of radical treatment (115). RvD1 and RvD2 suppress melanoma development (20). Furthermore, RvD1 or RvD2 inhibit lung metastasis of melanoma cells and regulate the production of chemokines and cytokines, including CCL4, CCL5, IL-6, IL-8, and TNF-α, by human macrophages, providing antitumor immunity.

CLINICAL TRIAL OF OMEGA3 PUFA FOR CUTANEOUS SKIN DISEASES

Finally, we reviewed the clinical trials of omega 3 PUFAs for cutaneous skin diseases. There are several trials for atopic dermatitis and psoriasis.

The intake of omega-3 supplement improves the Scoring in Atopic Dermatitis (SCORAD) score (116). A double-blind, randomized, placebo-controlled trial showed AD patients who received daily ω3 fatty acid supplementation (fish oil, 10%; 200 mL) show high serum EPA concentration and a decreased disease severity of AD (117).

Psoriasis patients with obesity received energy-restricted foods enriched of ω3 PUFAs (average 2.6 g/d), and these patients showed impaired Psoriasis Area Score Index (PASI)
score and Dermatological Life Quality Index (118). A double-blind, randomized study in multicenter trials showed the group of taking daily an ω3 fatty acid (Omegavenous; 200 ml/day with 4.2 gm of both EPA and DHA) decreased total PASI score without serious side effects (119).

Although there have been no clinical trials of cutaneous malignancies, head and neck squamous cell carcinoma has been reported. Supplementation of daily 2 g EPA intake impairs the production of serum pro-inflammatory cytokines, reduction of body weight and lean body mass, and increases quality of life in patients with squamous cell carcinoma in head and neck (120).

**CONCLUSION**

There are a limited number of research and clinical trials for investigations of the effects of ω3 PUFA in skin diseases. According to previous studies assessing immune cells, various beneficial effects are expected in skin diseases. Furthermore, there are few reports available on keratinocytes, which are a major component of cells present in the epidermis. The detailed action of keratinocytes in the skin needs to be clarified in future research. Because the incidences of inflammatory skin diseases and malignancies are currently increasing, future basic research and clinical trials for ω3 PUFAs in dermatology fields are expected give us a beneficial information for the daily treatment for skin diseases.

**AUTHOR CONTRIBUTIONS**

YS and MN wrote this manuscript, and NS-S conducted a critical review of this paper. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Pamerger ME, Hall JE, Tanabe Y, Simonson TS. Cross-Species Insights Into Genomic Adaptations to Hypoxia. *Front Genet* (2020) 11:743. doi: 10.3389/fgen.2020.00743
2. Stellingwerff T, Peeling P, Garvican-Lewis LA, Hall R, Koivisto AE, Heikura IA, et al. Nutrition and Altitude: Strategies to Enhance Adaptation, Improve Performance and Maintain Health: A Narrative Review. *Sports Med* (2019) 49(Suppl 2):169–84. doi: 10.1007/s40279-019-01159-w
3. Pereira LJ, van der Bilt A. The influence of oral processing, food perception and social aspects on food consumption: a review. *J Oral Rehabil* (2016) 43(8):630–48. doi: 10.1111/joor.12395
4. Causeret C, Bentejac M, Bugaut M. Proteins and enzymes of the oral processing, food perception and biological implications. *Curr Opin Clin Nutr Metab Care* (2004) 7(2):137–44. doi: 10.1007/s00169-2004-00006
5. Burdge GC, Wootton SA. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? *J Biol Chem* (2004) 279(5):651–42.
6. Burdge GC. Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. *Curr Opin Nutr Metab Care* (2004) 7(2):137–44. doi: 10.1007/s00169-2004-00006
7. Burdge GC, Calder PC. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. *Reprod Nutr Dev* (2005) 45(5):581–97. doi: 10.1051/rdn:2005047
8. Burdge GC, Jones AE, Wootton SA. Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men*. *Br J Nutr* (2002) 88(4):355–63. doi: 10.1079/BJN20022652
9. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in young women. *Br J Nutr* (2002) 88(4):411–20. doi: 10.1079/BJN2002689
10. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? *Lancet* (1978) 2(8081):117–9. doi: 10.1016/0140-6736(78)91505-2
11. Horrobin DF. Low prevalences of coronary heart disease (CHD), psoriasis, asthma and rheumatoid arthritis in Eskimos: are they caused by high dietary intake of eicosapentaenoic acid (EPA), a genetic variation of essential fatty acid (EFA) metabolism or a combination of both? *Med Hypotheses* (1987) 22(4):421–8. doi: 10.1016/0306-9877(87)90037-5
12. Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Cardiovascular Disease: A Science Advisory From the American Heart Association. *Circulation* (2017) 135(15):867–84. doi: 10.1161/CIR.0000000000000482
13. Siddiquee A, Patel M, Rajalingam S, Narke D, Kurade M, Ponnath DS. Effect of omega-3 fatty acid supplementation on resolvin (RvE1)-mediated suppression of inflammation in a mouse model of asthma. *Immunopharmacol Immunotoxicol* (2019) 41(2):250–7. doi: 10.1080/08923973.2019.1584903
14. Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, et al. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. *Inflamm Bowel Dis* (2010) 16(1):87–95. doi: 10.1002.ibd.21029
15. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. *Nature* (2007) 447(7146):869–74. doi: 10.1038/nature05877
16. Takamya R, Fukunaga K, Arita M, Miyata J, Seki H, Minematsu N, et al. Resolvin E1 maintains macrophage function under cigarette smoke-induced oxidative stress. *FEBS Open Bio* (2012) 2:328–33. doi: 10.1016/j.fob.2012.10.001
17. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. *J Clin Invest* (2011) 121(2):569–81. doi: 10.1172/JCI42545
18. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. *J Biol Chem* (2010) 285(5):3451–61. doi: 10.1074/jbc.M109.044131
19. Hong S, Porter TF, Lu Y, Oh SF, Pillai PS, Serhan CN. Resolvin E1 metabolome in local inactivation during inflammation-resolution. *J Immunol* (2008) 180(5):3512–9. doi: 10.4049/jimmunol.180.5.3512
20. Sulciner ML, Serhan CN, Gilligan MM, Mudge DK, Chang J, Gartner U, et al. Resolvins suppress tumor growth and enhance cancer therapy. *J Exp Med* (2018) 215(1):115–40. doi: 10.1084/jem.20170681
21. Liu G, Gong Y, Zhang R, Piao L, Li X, Liu Q, et al. Resolvin E1 attenuates injury-induced vascular neointimal formation by inhibition of inflammatory responses and vascular smooth muscle cell migration. *FASEB J* (2018) 32(10):5413–25. doi: 10.1096/fj.201800173R
22. Sawada Y, Honda T, Hanakawa S, Nakamizo S, Murata T, Ueharuguchi-Tanada Y, et al. Resolvin E1 inhibits dendritic cell migration in the skin and attenuates contact hypersensitivity responses. *J Exp Med* (2015) 212(11):1921–30. doi: 10.1084/jem.20150381
23. Arita M, Bianchini F, Alberti J, Sher A, Chiang N, Hong S, et al. Stereochmical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J Exp Med* (2005) 205(5):713–22. doi: 10.1084/jem.20042301
24. Wang H, Zhao Q, Luo D, Yin Y, Li T, Zhang W, et al. The Anti-inflammatory Mediator Resolvin E1 Protects Mice Against Lipopolysaccharide-Induced Heart Injury. *Front Pharmacol* (2020) 11:203. doi: 10.3389/fphar.2020.00203
39. Hua J, Jin Y, Chen Y, Inomata T, Lee H, Chauhan SK, et al. The resolvin D1
38. Caron JP, Gandy JC, Brown JL, Sordillo LM. Docosahexaenoic acid-derived
26. Haas-Stapleton EJ, Lu Y, Hong S, Arita M, Favoreto S, Nigam S, et al. Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes.
27. Unno Y, Sato Y, Fukuda H, Ishimura K, Ikeda H, Watanabe M, et al. Resolvin D1 promotes resolution of lung in
26. Haas-Stapleton EJ, Lu Y, Hong S, Arita M, Favoreto S, Nigam S, et al.
27. Unno Y, Sato Y, Fukuda H, Ishimura K, Ikeda H, Watanabe M, et al.
28. Herrera BS, Hasturk H, Kantarci A, Freire MO, Nguyen K, Kansal S, et al.
29. Isobe Y, Arita M, Iwamoto R, Urabe D, Todoroki H, Masuda K, et al.
30. Isobe Y, Arita M, Iwamoto R, Urabe D, Todoroki H, Masuda K, et al.
31. Isobe Y, Arita M, Iwamoto R, Urabe D, Todoroki H, Masuda K, et al.
32. Isobe Y, Arita M, Iwamoto R, Urabe D, Todoroki H, Masuda K, et al.
33. Isobe Y, Arita M, Iwamoto R, Urabe D, Todoroki H, Masuda K, et al.
34. Isobe Y, Arita M, Iwamoto R, Urabe D, Todoroki H, Masuda K, et al.
35. Isobe Y, Arita M, Iwamoto R, Urabe D, Todoroki H, Masuda K, et al.
36. Abdulnour RE, Sham HP, Douda DN, Colas RA, Dalli J, Bai Y, et al.
37. Abdulnour RE, Sham HP, Douda DN, Colas RA, Dalli J, Bai Y, et al.
38. Caron JP, Gandy JC, Brown JL, Sordillo LM. Docosahexaenoic acid-derived
39. Hua J, Jin Y, Chen Y, Inomata T, Lee H, Chauhan SK, et al. The resolvin D1
40. Wang CS, Maruyama CL, Easley JT, Trump BG, Baker OJ. AT-RvD1 promotes Resolution of Inflammation in NOD/ShiLtJ mice.
41. Hua J, Jin Y, Chen Y, Inomata T, Lee H, Chauhan SK, et al. The resolvin D1
42. Abdulnour RE, Sham HP, Douda DN, Colas RA, Dalli J, Bai Y, et al. Aspirin-triggered resolvin D1 protects the liver from ischemia/reperfusion injury by enhancing M2 macrophage polarization and effectorcytosis. Biochim Biophys Acta (2016) 1861(9 Pt A):1025–35. doi: 10.1016/j.bbalip.2016.06.002
43. hsiao HM, Saptinoro RE, Thaxter TH, Crossadell A, Levy EP, Fulton RA, et al. A novel anti-inflammatory and pro-resolving role for resolvins D1 in acute cigarette smoke-induced lung inflammation. PLoS One (2013) 8(3):e58258. doi: 10.1371/journal.pone.0058258
44. Shan K, Feng N, Cui J, Wang S, Qu H, Fu G, et al. Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization. J Cell Mol Med (2020) 24(14):8045–56. doi: 10.1111/jcmm.15436
45. Wang CS, Maruyama CL, Easley JT, Trump BG, Baker OJ. AT-RvD1 promotes Resolution of Inflammation in NOD/ShiLtJ mice.
46. Sawada et al. Omega 3 Fatty Acid and Skin Diseases
62. Yaxin W, Shanglong Y, Huajing S, Hong L, Shiyang Y, Xiangdong C, et al. Resolvin D1 attenuates lipopolysaccharide induced acute lung injury through CXCL-12/CXCR4 pathway. J Surg Res (2014) 188(1):213–21. doi:10.1016/j.jss.2013.11.1107

63. Sekheri M, El Kebir D, Edner N, Filep JG, 15-Epi-LXA4(1) and 17-epi-RvD1 restore TLR9-mediated impaired neutrophil phagocytosis and accelerate resolution of lung inflammation. Proc Natl Acad Sci U S A (2020) 117(14):7971–80. doi:10.1073/pnas.1920193117

64. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, et al. Eosinophil-mediated signalling attenuates in allergic responses in diverse forms of macrophage activation and polarization. Trends Immunol (2018) 39(5):265–73. doi:10.1016/j.it.2018.02.003

65. Mizraji G, Heyman O, Van Dyke TE, Wilensky A. Resolvin D2 Restrains Th1 Immunity and Prevents Alveolar Bone Loss in Murine Periodontitis. Front Immunol (2018) 9:785. doi:10.3389/fimmu.2018.00785

66. Bohr S, Patel SL, Sarin D, Irimia D, Wilensky A. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. J Clin Invest (2019) 129(12):5294–311. doi:10.1172/JCI129448

67. Norris PC, Arnardottir H, Sanger JM, Fichtner D, Keyes GS, Serhan CN. Protective lipid mediators derived from omega-3 polyunsaturated fatty acids attenuate adipose tissue inflammation in ob/ob and diet-induced obese mice. FASEB J (2017) 31(5):2135–45. doi:10.1096/fj.201600859R

68. Dalli J, Winkler JW, Colas RA, Arnardottir H, Cheng CY, Chiang N, et al. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis. Exp Eye Res (2015) 134:797–1805. doi:10.1016/j.exer.2015.02.005

69. Colby JK, Abdulnour RE, Sham HP, Dalli J, Colas RA, Winkler JW, et al. Proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J Immunol (2013) 191(8):4288–98. doi:10.4049/jimmunol.1202743

70. Zhang P, Yin Y, Wang T, Li W, Li C, Zeng X, et al. Maresin 1 mitigates concanavalin A-induced acute liver injury in mice by inhibiting ROS-mediated activation of NF-kB signaling. Free Radic Biol Med (2020) 147:23–36. doi:10.1016/j.freeradbiomed.2019.11.033

71. Martinez-Fernandez L, Gonzalez-Muniesa P, Laiglesia LM, Sainz N, Prieto-Hontoria PL, Escoté X, et al. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. FASEB J (2017) 31(5):2135–45. doi:10.1096/fj.201600859R

72. Chiang N, Liberros S, Norris PC, de la Rosa X, Serhan CN. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. FASEB J (2017) 31(5):2135–45. doi:10.1096/fj.201600859R

73. Jin S, Chen H, Li Y, Zhong H, Sun W, Wang J, et al. Maresin 1 improves the Trend/Th17 imbalance in rheumatoid arthritis through mTOR. Ann Rheum Dis (2018) 77(11):1644–52. doi:10.1136/annrheumdis-2018-213511

74. Gong J, Wu ZY, Qi H, Chen L, Li HB, Li B, et al. Maresin 1 mitigates LPS-induced acute lung injury in mice. Br J Pharmacol (2014) 171(14):3539–50. doi:10.1111/bph.12714

75. Tan Q, Che C, Lin J, He H, Zhao W, Lv L, et al. Maresin1 regulates neutrophil recruitment and IL-10 expression in Aspergillus fumigatus keratitis. Int Immunopharmacol (2019) 69:103–8. doi:10.1016/j.intimp.2019.01.032

76. Norris PC, Arnardottir H, Sanger JM, Keyes GS, Serhan CN. Resolvin D3 multi-level proresolving actions are host protective during infection. Prostagland Leukot Essent Fatty Acids (2018) 138:81–9. doi:10.1016/j.prostaglandins.2016.01.001

77. Marcon R, Bento AF, Dutra RC, Bicca MA, Leite DF, Calixto JB. Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, protects against oxidative stress-induced apoptosis. J Biol Chem (2019) 294(5):26536–363. doi:10.1016/j.jbc.2019.01.032

78. Huang R, Vi L, Zong X, Baht GS, Bazan NG. Maresin 1 resolves aged-associated inflammation and oxidative stress caused by UVB irradiation. Sci Rep (2019) 9(1):3062. doi:10.1038/s41598-019-39584-6
100. Hong S, Tian H, Lu Y, Laborde JM, Muhale FA, Wang Q, et al. Neuroprotectin/protectin D1: endogenous biosynthesis and actions on diabetic macrophages in promoting wound healing and innervation impaired by diabetes. *Am J Physiol Cell Physiol* (2014) 307(11):C1058–67. doi: 10.1152/ajpcell.00270.2014

101. Ye Y, Scheff NN, Bernabe D, Salvo E, Ono K, Liu C, et al. Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma. *Neuropharmacology* (2018) 139:182–93. doi: 10.1016/j.neuropharm.2018.07.016

102. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. *J Immunol* (2018) 201 (6):1605–13. doi: 10.4049/jimmunol.1800013

103. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. *J Allergy Clin Immunol* (2017) 140(3):645–53. doi: 10.1016/j.jaci.2017.07.004

104. Tokuyama M, Mabuchi T. New Treatment Addressing the Pathogenesis of Psoriasis. *Neuropharmacology* (2018) 139:182–93. doi: 10.1016/j.neuropharm.2018.07.016

105. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Adv Immunol* (2016) 133:105–30. doi: 10.1016/bs.ai.2016.03.001

106. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Perivascular leukocyte clusters are a major predisposing factor for atopic dermatitis. *Nat Genet* (2006) 38 (4):441–6. doi: 10.1038/ng1767

107. Kawasahi H, Nagao K, Kubo A, Hata T, Shimizu A, Mizuno H, et al. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. *J Allergy Clin Immunol* (2012) 129(6):e1538–46.e6. doi: 10.1016/j.jaci.2012.01.068

108. Nakatsuji T, Chen TH, Two AM, Chun KA, Narala S, Gehr RS, et al. Staphylococcus aureus Exploits Epidermal Barrier Defects in Atopic Dermatitis to Trigger Cytokine Expression. *J Invest Dermatol* (2016) 136 (11):2192–200. doi: 10.1016/j.jid.2016.05.027

109. Sawada Y, Honda T, Nakamizo S, Nakajima S, Nonomura Y, Otsuka A, et al. Prostaglandin E2 (PGE2)-EP2 signaling negatively regulates murine atopic dermatitis-like skin inflammation by suppressing thymic stromal lymphopoiesis expression. *J Allergy Clin Immunol* (2019) 144(5):1265–73.e9. doi: 10.1016/j.jaci.2019.06.036

110. Honda T, Egawa G, Grabelle S, Kabashima K. Update of immune events in the murine contact hypersensitivity model: toward the understanding of allergic contact dermatitis. *J Invest Dermatol* (2013) 133(2):303–15. doi: 10.1038/ jid.2012.284

111. Natsuki Y, Egawa G, Nakamizo S, Ono S, Hanakawa S, Okada T, et al. Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. *Nat Immunol* (2014) 15(11):1064–9. doi: 10.1038/ni.2992

112. Bernard JJ, Gallo RL, Krutmann J. Photoimmunology: how ultraviolet radiation affects the immune system. *Nat Rev Immunol* (2019) 19(11):688–701. doi: 10.1038/s41577-019-0205-z

113. Martin P, Nunan R. Cellular and molecular mechanisms of repair in acute and chronic wound healing. *Br J Dermatol* (2015) 173(2):370–8. doi: 10.1111/bjd.13954

114. Burton KA, Ashack KA, Khachemoune A. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. *Am J Clin Dermatol* (2017) 18(3):491–508. doi: 10.1007/s40257-016-0207-3

115. Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. *J Invest Dermatol* (2020) 141(1):23–31. doi: 10.1016/j.jid.2020.03.943

116. Eriksen BB, Bäre DL. Open trial of supplements of omega 3 and 6 fatty acids, vitamins and minerals in atopic dermatitis. *J Dermatol Treat* (2016) 27 (2):82–5. doi: 10.1080/0954663060621946

117. Mayser P, Mayer K, Mahloudjian M, Benzing S, Krämer HJ, Schull WB, et al. A double-blind, randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis. *JPEN J Parenter Enteral Nutr* (2002) 26(3):151–8. doi: 10.1177/0148607102026003151

118. Guida B, Napoleone A, Trio R, Nastasi A, Balato N, Lacetti R, et al. Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. *Clin Nutr (Edinburgh Scotland)* (2014) 33(3):399–405. doi: 10.1016/j.clnu.2013.09.010

119. Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, Welty FK. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. *FASEB J Off Publ Fed Am Societies Exp Biol* (2016) 30(8):2792–801. doi: 10.1096/fj.201500155R

120. Solís-Martínez O, Plasa-Carvalho V, Phillips-Sixtos G, Trujillo-Cabrería Y, Hernández-Cuellar A, Queipo-Garcia GE, et al. Effect of Eicosapentaenoic Acid on Body Composition and Inflammation Markers in Patients with Head and Neck Squamous Cell Cancer from a Public Hospital in Mexico. *Nutr Cancer* (2018) 70(4):663–70. doi: 10.1080/01635581.2018.1460678

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Sawada, Saito-Sasaki and Nakamura. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.